Condition pulmonary hypertension
Treatment fdg pet scan
Sponsor Ottawa Heart Institute Research Corporation
Start date December 2014
End date November 2018
Trial size 10 participants
Trial identifier NCT02237378, 20140602


Right ventricular (RV) failure is the leading cause of death in pulmonary arterial hypertension. (PAH) Right ventricular ejection fraction is one of the most important predictors of prognosis in heart failure patients regardless of cause. It is estimated that 30-50% of patients with heart failure and preserved ejection fraction (HFpEF) have right ventricular dysfunction and up to 70% of these patients will have significant pulmonary hypertension (PH), both of which are related to much worse prognosis. Right ventricular failure is becoming an increasingly prevalent and significant cause of morbidity in patients with left heart disease. Despite the significance of RV function to survival, there are no therapies available that directly or selectively improve RV function.

The overall theme of this research project is to evaluate the mechanisms that contribute to the cause of right heart failure. This small study is designed to look at the role of heart and lung metabolism and pulmonary hypertension as they relate to the development of right heart failure in cardiovascular disease.(PH-LHD)

Recruiting in the following locations…

United States No locations recruiting
Other countries Canada

Study Design

Intervention model single group assignment
Primary purpose basic science
Masking no masking
A PET scan using F-18 FDG, N-13 Ammonia will be performed
fdg pet scan F-18-FDG
Following an overnight fast, subjects will be positioned in the Discovery 660 PET/VCT scanner. Following a scout scan to confirm patient positioning, low dose xray CT scan is performed for photon attenuation. A 20 minute dynamic PET scan is started simultaneously with 3 MBq/kg of N-13 ammonia to measure myocardial perfusion. Following N-13 decay,a 60 minute dynamic PET scan with 3 MBq/kg F-18- FDG to measure myocardial glucose uptake. Blood sampling for glucose and insulin will occur at pre specified time points throughout the scan.

Primary Outcomes

Cardiac and pulmonary metabolism role in development of right heart failure in pulmonary hypertension in left heart disease.
time frame: Baseline

Eligibility Criteria

All participants at least 18 years old.

Inclusion Criteria: - Patients must be able to provide their written informed consent to participate in the study after having received adequate previous information and prior to any study specific procedures. - At least 18 years of age at the time of screening. - Patients with PH secondary to left heart disease (known as group II PH) defined as a mean PAP>25 mmHg and a PCWP of ≥15 mmHg. Exclusion Criteria: - All other types of pulmonary hypertension including Dana Point Classification Group 1, 3, 5. - Type II Diabetes mellitus requiring medical therapy - Previous myocardial infarction within the 3 months prior to screening. - Renal insufficiency (glomerular filtration rate < 30 ml/min. - ALT or AST > 3times ULN and/or severe hepatic insufficiency. - Contraindication to MRI imaging.

Additional Information

Official title Evaluation of Cardiopulmonary Metabolism and Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Left Heart Disease
Principal investigator Lisa M Mielniczuk, MD
Description The hemodynamic definition of PH-LHD involves a mean pulmonary artery pressure (mPAP) >25mm Hg at rest and pulmonary capillary wedge pressure (PCWP) of ≥15.The coexistence of mitral insufficiency is also a characteristic of PH-LHD. HFpEF is a condition caused by impaired relaxation of a stiffened myocardium as a consequence of an increased load to the left ventricle due to elevated systemic pressures. Pulmonary hemodynamics can be used to classify PH LHD as either passive or reactive, irrespective of LV function. It has been suggested that diastolic pressure gradient (DPG) may offer added prognostic value as a more accurate indicator of pulmonary vascular remodeling.
Trial information was received from ClinicalTrials.gov and was last updated in January 2017.
Information provided to ClinicalTrials.gov by Ottawa Heart Institute Research Corporation.